Chinese Journal of Pharmacovigilance ›› 2015, Vol. 12 ›› Issue (8): 509-510.
Previous Articles Next Articles
YIN Wen-jie, WANG Dong-xue, SUN Lu
Received:2015-09-02
Revised:2015-09-02
Online:2015-08-08
Published:2015-09-02
CLC Number:
YIN Wen-jie, WANG Dong-xue, SUN Lu. One Case of Anaphylactic Shock Induced by Shenmai Injection[J]. Chinese Journal of Pharmacovigilance, 2015, 12(8): 509-510.
| [1] 余键,辛艳飞,宣尧仙.参麦注射液药理作用的物质基础研究进展[J].中国医药导报,2013,32（4）：497-499. [2] 万凯化,高菁,付辉政,等.参麦注射液致349例不良反应病例报告分析[J].中国药物滥用防治杂志,2014,20（2）:71-73. [3] 雷招宝.参麦注射液致过敏性休克23例文献分析[J].中国药房,2012,23（12）：1133-1135. [4] 李荣,蒋英蓝,曾敬怀,等.中药注射剂发生不良反应的相关性研究进展[J].中成药,2013,35（5）:1059-1061. [5] 关溪,徐德生.参麦注射液致过敏性休克文献分析[J].药物流行病学杂志,2013,22（1）:43-45. [6] 朱月琴,刘产明,黄玮.参麦注射液引起过敏性休克的循证分析与评价[J].中国医院药学杂志,2014,34（13）：1102-1105. [7] 黎颖然、潘泰先.170例参麦注射液不良反应文献分析[J].中国药物警戒,2010,7（10）：623-625. |
| [1] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
| [2] | MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172. |
| [3] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
| [4] | GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5. |
| [5] | MA Li’na, HU Xiaozhen, ZHENG Changhui, SUN Ying, ZHAO Xu, CAO Junling, XIAO Xiaohe. Visual analysis of knowledge map of toxic Chinese medicine Changshan toxicity-effect transformation based the thought of “yin du wei neng” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 25-32. |
| [6] | LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101. |
| [7] | TIAN Chunhua, WU Guizhi. Implementation of periodic benefit risk evaluation reports in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384. |
| [8] | ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang. Post-marketing active monitoring of medical devices under vigilance [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390. |
| [9] | PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263. |
| [10] | WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089. |
| [11] | JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094. |
| [12] | LIU Hongliang, WANG Qing, HOU Yongfang. Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1095-1098. |
| [13] | XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970. |
| [14] | LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977. |
| [15] | SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
